| Diffuse Large B-Cell Lymphoma
Polivy vs Yescarta
Side-by-side clinical, coverage, and cost comparison for diffuse large b-cell lymphoma.Deep comparison between: Polivy vs Yescarta with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsYescarta has a higher rate of injection site reactions vs Polivy based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Yescarta but not Polivy, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Polivy
Yescarta
At A Glance
IV infusion
Every 21 days
CD79b-directed antibody-drug conjugate
IV infusion
Single infusion
CD19-directed CAR T cell immunotherapy
Indications
- Diffuse Large B-Cell Lymphoma
- Diffuse Large B-Cell Lymphoma
- Diffuse Large B-Cell Lymphoma
- Mediastinal (Thymic) Large B-Cell Lymphoma
- High grade B-cell lymphoma
- Lymphoma, Follicular
Dosing
Diffuse Large B-Cell Lymphoma (previously untreated), HGBL 1.8 mg/kg IV infusion every 21 days for 6 cycles in combination with rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP); administer initial dose over 90 minutes, subsequent doses may be given over 30 minutes if tolerated.
Diffuse Large B-Cell Lymphoma (relapsed or refractory) 1.8 mg/kg IV infusion every 21 days for 6 cycles in combination with bendamustine and a rituximab product; administer initial dose over 90 minutes, subsequent doses may be given over 30 minutes if tolerated.
Diffuse Large B-Cell Lymphoma, Mediastinal (Thymic) Large B-Cell Lymphoma, High grade B-cell lymphoma Target dose 2 x 10^6 CAR-positive viable T cells per kg body weight (max 2 x 10^8 cells) as a single IV infusion; pretreat with cyclophosphamide 500 mg/m2 IV and fludarabine 30 mg/m2 IV on days -5, -4, and -3 before infusion.
Lymphoma, Follicular Target dose 2 x 10^6 CAR-positive viable T cells per kg body weight (max 2 x 10^8 cells) as a single IV infusion; pretreat with cyclophosphamide 500 mg/m2 IV and fludarabine 30 mg/m2 IV on days -5, -4, and -3 before infusion.
Contraindications
—
—
Adverse Reactions
Most common (>=20%) Peripheral neuropathy, neutropenia, thrombocytopenia, anemia, fatigue, diarrhea, nausea, constipation, alopecia, mucositis, pyrexia, decreased appetite
Serious Peripheral neuropathy, infusion-related reactions, myelosuppression, serious and opportunistic infections, progressive multifocal leukoencephalopathy, tumor lysis syndrome, hepatotoxicity, infusion site extravasation injury
Most common (>=30%) CRS, fever, hypotension, encephalopathy, fatigue, tachycardia, headache, nausea, febrile neutropenia, diarrhea, musculoskeletal pain, infections with pathogen unspecified, chills, decreased appetite
Serious CRS, fever, encephalopathy, hypotension, infection with unspecified pathogen, pneumonia, febrile neutropenia, cardiac arrhythmia, cardiac failure, aphasia, hypoxia
Postmarketing Spinal cord edema, myelitis, quadriplegia, dysphagia, status epilepticus, infusion related reactions, T cell malignancies
Pharmacology
Polatuzumab vedotin-piiq is a CD79b-directed antibody-drug conjugate; the monoclonal antibody binds CD79b on B cells, is internalized, and releases MMAE intracellularly via lysosomal protease cleavage, where MMAE binds microtubules to inhibit cell division and induce apoptosis in dividing B cells.
CD19-directed genetically modified autologous T cell immunotherapy; upon engagement with CD19-expressing target cells, the CD28 and CD3-zeta co-stimulatory domains activate downstream signaling cascades leading to T cell activation, proliferation, and killing of CD19-expressing cancer cells and normal B cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Polivy
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
Yescarta
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Polivy
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Yescarta
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Polivy
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Yescarta
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableCancerCare: Non-Hodgkin Lymphoma
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableCancerCare: Non-Hodgkin Lymphoma
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
PolivyView full Polivy profile
YescartaView full Yescarta profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.